| AJCC cancer staging manual S Edition, S Edge, D Byrd AJCC cancer staging manual, 2017 | 9184 | 2017 |
| Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive … ML Citron, DA Berry, C Cirrincione, C Hudis, EP Winer, WJ Gradishar, ... Journal of clinical oncology 21 (8), 1431-1439, 2003 | 2069 | 2003 |
| Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast … IC Henderson, DA Berry, GD Demetri, CT Cirrincione, LJ Goldstein, ... Journal of clinical oncology 21 (6), 976-983, 2003 | 1731 | 2003 |
| A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer RS Sandler, S Halabi, JA Baron, S Budinger, E Paskett, R Keresztes, ... New England Journal of Medicine 348 (10), 883-890, 2003 | 1479 | 2003 |
| American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict … CJ Allegra, JM Jessup, MR Somerfield, SR Hamilton, EH Hammond, ... Journal of clinical oncology 27 (12), 2091-2096, 2009 | 1478 | 2009 |
| Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non–small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy … GM Strauss, JE Herndon, MA Maddaus, DW Johnstone, EA Johnson, ... Journal of clinical oncology 26 (31), 5043, 2008 | 1134 | 2008 |
| Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303) HL Kindler, D Niedzwiecki, D Hollis, S Sutherland, D Schrag, H Hurwitz, ... Journal of Clinical Oncology 28 (22), 3617, 2010 | 987 | 2010 |
| American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options LE Schnipper, NE Davidson, DS Wollins, C Tyne, DW Blayney, D Blum, ... Journal of Clinical Oncology 33 (23), 2563-2577, 2015 | 984 | 2015 |
| Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review JD Merker, GR Oxnard, C Compton, M Diehn, P Hurley, AJ Lazar, ... Archives of pathology & laboratory medicine 142 (10), 1242-1253, 2018 | 948 | 2018 |
| Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803 JA Meyerhardt, D Heseltine, D Niedzwiecki, D Hollis, LB Saltz, RJ Mayer, ... J Clin Oncol 24 (22), 3535-3541, 2006 | 915 | 2006 |
| UGT1A1* 28 polymorphism as a determinant of irinotecan disposition and toxicity L Iyer, S Das, L Janisch, M Wen, J Ramirez, T Karrison, GF Fleming, ... The pharmacogenomics journal 2 (1), 43-47, 2002 | 843 | 2002 |
| Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a … AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, B Fruth, JA Meyerhardt, ... Jama 317 (23), 2392-2401, 2017 | 826 | 2017 |
| Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development GJ Kelloff, JM Hoffman, B Johnson, HI Scher, BA Siegel, EY Cheng, ... Clinical Cancer Research 11 (8), 2785-2808, 2005 | 806 | 2005 |
| Toxic effects of cis-dichlorodiammineplatinum (II) in man. DD Von Hoff, R Schilsky, CM Reichert, RL Reddick, M Rozencweig, ... Cancer treatment reports 63 (9-10), 1527-1531, 1979 | 723 | 1979 |
| Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received LE Schnipper, NE Davidson, DS Wollins, DW Blayney, AP Dicker, ... Journal of Clinical Oncology 34 (24), 2925-2934, 2016 | 653 | 2016 |
| First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin J Cassidy, C Twelves, E Van Cutsem, P Hoff, E Bajetta, M Boyer, R Bugat, ... Annals of oncology 13 (4), 566-575, 2002 | 647 | 2002 |
| CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts … AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, MR Mahoney, BH O'Neil, ... Journal of Clinical Oncology 32 (15_suppl), LBA3-LBA3, 2014 | 645 | 2014 |
| Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and … GM Strauss, J Herndon, MA Maddaus, DW Johnstone, EA Johnson, ... Journal of Clinical Oncology 22 (14_suppl), 7019-7019, 2004 | 585 | 2004 |
| Recommendations for management of patients with neuroendocrine liver metastases A Frilling, IM Modlin, M Kidd, C Russell, S Breitenstein, R Salem, ... The lancet oncology 15 (1), e8-e21, 2014 | 576 | 2014 |
| Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials E Van Cutsem, PM Hoff, P Harper, RM Bukowski, D Cunningham, ... British journal of cancer 90 (6), 1190-1197, 2004 | 530 | 2004 |
